Stock listing

NASDAQ:INVA Innoviva, Inc. Stock

Home listing (NASDAQ) of Innoviva, Inc.

Follow Innoviva, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:INVA

$18.41 USD +0.01 (+0.1%)

Close on Nov 20, 2026

Past year -13.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$18.33 – $18.79 USDNov 20, 2026
Volume
1.15M sharesNov 20, 2026
Market cap
$1.33B USDAt the close on Nov 20, 2026 · price × 72.25M shares outstanding
52-week range
$18.23 – $25.15 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$17.58M USDMedian day 712,630 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Innoviva, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:INVA · Home$18.41 USD+0.01 (+0.1%)1,146,551$18.41$18.79$18.33$18.40Close on Nov 20, 2026
Frankfurt:HVE€16.70 EUR0.00 (0.0%)—€16.70€16.70€16.70€16.70Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INVA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$18.41+0.01+0.1%$18.41$18.79$18.331,146,551
$18.40+0.10+0.5%$18.32$18.54$18.231,188,587
$18.30-0.19-1.0%$18.39$18.58$18.28988,415
$18.49-0.54-2.8%$19.08$19.24$18.41814,143
$19.03+0.06+0.3%$19.11$19.23$18.95560,889
$18.97+0.11+0.6%$18.99$19.24$18.86563,479
$18.86-0.22-1.2%$18.97$19.03$18.66649,315
$19.08+0.08+0.4%$20.10$20.10$18.80786,108
$19.00-0.10-0.5%$19.19$20.00$18.731,662,134
$19.10-0.14-0.7%$19.54$19.87$19.021,654,267
$19.24-2.02-9.5%$20.59$20.87$19.192,649,666
$21.26+0.33+1.6%$21.28$21.52$21.03922,344
$20.93-0.09-0.4%$21.07$21.39$20.90712,630
$21.02-0.20-0.9%$21.62$21.62$20.891,120,571
$21.22-0.09-0.4%$21.48$21.60$21.13623,266
$21.31+0.19+0.9%$21.41$21.52$21.12626,925
$21.12+0.18+0.9%$20.85$21.15$20.74585,271
$20.94-0.11-0.5%$20.97$21.06$20.75584,406
$21.05+0.39+1.9%$20.77$21.22$20.77569,075
$20.66-0.40-1.9%$20.88$20.94$20.51978,553
$21.06+0.15+0.7%$21.05$21.27$20.92452,078
$20.91-0.37-1.7%$21.20$21.36$20.89442,222
$21.28+0.20+0.9%$21.31$21.49$21.12507,563
$21.08+0.30+1.4%$20.68$21.15$20.68590,514
$20.78-0.08-0.4%$20.97$20.97$20.56550,500
$20.86-0.11-0.5%$21.33$21.76$20.83673,000
$20.97+0.23+1.1%$20.79$21.18$20.73673,500
$20.74-0.71-3.3%$21.55$21.55$20.71811,600
$21.45+0.24+1.1%$21.27$21.48$21.12521,200
$21.21+0.34+1.6%$20.80$21.28$20.78507,500
$20.87-0.19-0.9%$21.05$21.05$20.73612,300
$21.06+0.23+1.1%$20.78$21.10$20.78636,300
$20.83+0.19+0.9%$20.78$20.97$20.62679,600
$20.64+0.14+0.7%$20.53$20.74$20.45993,400
$20.50-0.05-0.2%$20.60$20.76$20.50774,700
$20.55-0.66-3.1%$21.28$21.28$20.53927,100
$21.21+0.10+0.5%$21.11$21.45$21.061,100,100
$21.11-0.12-0.6%$21.19$21.19$20.74555,800
$21.23+0.49+2.4%$20.74$21.39$20.59854,600
$20.74+0.08+0.4%$20.70$20.78$20.35623,400
$20.66+0.42+2.1%$20.28$20.79$20.281,368,100
$20.24-0.74-3.5%$21.11$21.36$20.234,031,100
$20.98-0.06-0.3%$21.17$21.39$20.96931,600
$21.04-0.10-0.5%$21.10$21.27$21.00688,500
$21.14+0.09+0.4%$20.93$21.18$20.851,437,000
$21.05-0.15-0.7%$21.22$21.42$21.001,251,900
$21.20+0.36+1.7%$20.86$21.24$20.86715,400
$20.84-0.06-0.3%$20.86$20.88$20.501,102,000
$20.90+0.24+1.2%$20.93$21.11$20.69885,400
$20.66+0.04+0.2%$20.84$20.88$20.45727,300
$20.62-0.51-2.4%$21.16$21.24$20.58836,400
$21.13-0.21-1.0%$21.16$21.41$20.77847,400
$21.34+0.010.0%$21.06$21.51$20.87782,800
$21.33-0.02-0.1%$21.20$21.36$21.09563,500
$21.350.000.0%$21.48$21.48$21.04612,300
$21.35+0.27+1.3%$21.27$21.48$21.22600,600
$21.08+0.31+1.5%$20.97$21.18$20.94798,700
$20.77-0.20-1.0%$20.97$21.05$20.68877,300
$20.97+0.010.0%$20.96$21.07$20.80527,000
$20.96-0.28-1.3%$20.99$21.10$20.86488,100
$21.24+0.07+0.3%$21.15$21.33$20.84693,000
$21.17+0.14+0.7%$21.10$21.24$20.93412,689
$21.03-0.04-0.2%$21.07$21.10$20.89510,303
$21.07+0.07+0.3%$21.01$21.23$20.90499,400
$21.00-0.48-2.2%$21.34$21.41$20.87796,500

Splits

1 split · NASDAQ:INVA · every price before a split is adjusted for it

DayRatioWhat
103-for-83Split
Ticker
NASDAQ:INVA
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Innoviva, Inc. news

Innoviva, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
14 in the last 12 months · 90 in all · newest Nov 4, 2026 · oldest 2019
Decks
17 decks · latest August 2026

Where Innoviva, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:INVA · Home listing · This pageNASDAQUnited StatesUSD
gettex:HVEgettexGermanyEUR
LS Exchange:A2AC9ULS ExchangeGermanyEUR
Lang & Schwarz:A2AC9ULang & SchwarzGermanyEUR
Frankfurt:HVEFrankfurtGermanyEUR
BOATS:INVABOATSUnited StatesUSD
Tradegate:HVETradegateGermanyEUR
Munich:HVEMunichGermanyEUR
BX Swiss:HVEBX SwissSwitzerlandCHF
Dusseldorf:HVEDusseldorfGermanyEUR
Stuttgart:HVEStuttgartGermanyEUR

Valuation

P/E 6.9× against a median of 40.6×: the lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$998.8M USD
P/E
6.9×
EV/sales
2.3×
EV/EBITDA
4.7×
Price/book
1.2×
Gross margin
74.5%
Operating margin
38.8%
Net margin
44.1%
Debt to equity
0.2×
Beta vs S&P 500
0.29

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Innoviva, Inc. · NASDAQ:INVAUS$1.33BUS$998.8M6.9×2.3×4.7×1.2×44.1%0.2×0.29
Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675US$1.47BUS$1.41B46.5×3.6×n/a2.2×8.0%0.1×n/a
Fujian Haixi Pharmaceuticals Co., Ltd. Class H · HKEX:2637US$1.45BUS$1.27B54.5×14.5×41.2×5.8×30.4%0.0×n/a
Marksans Pharma Limited · NSE:MARKSANSUS$1.42BUS$1.35B23.6×3.7×16.0×4.0×16.5%0.1×n/a
Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A · SZSE:002020US$1.41BUS$1.23B13.2×2.0×n/a1.6×17.5%0.0×n/a
Chengdu Olymvax Biopharmaceuticals Inc. Class A · SSE:688319US$1.37BUS$1.40Bn/a11.7×n/a10.2×−4.0%0.4×n/a
Celltrion Pharm Inc. · KRX:068760US$1.34BUS$1.24B42.0×2.9×19.6×4.0×7.4%0.0×n/a
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A · SZSE:300026US$1.31BUS$1.07Bn/an/an/a1.0×n/a0.0×n/a
Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A · SZSE:002099US$1.30BUS$1.18Bn/a3.9×n/a1.9×−11.6%0.0×n/a
Concord Biotech Ltd. · NSE:CONCORDBIOUS$1.24BUS$1.19B40.6×9.4×27.3×5.5×24.1%0.0×n/a
Zhejiang Xianju Pharmaceutical Co., Ltd. Class A · SZSE:002332US$1.24BUS$1.08B17.7×1.9×n/a1.4×12.0%0.0×n/a
Median of the othersUS$1.35BUS$1.24B40.6×3.7×23.4×3.1×12.0%0.0×

Forecasts

4 strong buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
34.80 USD · Analysts' mean
EPS, year to Dec 2026
0.86 · 5 analysts
Revenue, year to Dec 2026
434.5M · 4 analysts

Team and board

Officers

OfficerRole
Pavel RaifeldChief Executive Officer
David PattiCorporate Communications
Eleanor BarisserInvestor Relations Internal
Irwin TendlerHead of Investor Relations
David AltaracChief Medical Officer, IST
Marianne ZhenChief Accounting Officer

Board

DirectorRole
Jules HaimovitzChairman of the Board
Josephine LindenBoard Member
Sarah J. SchlesingerBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−9.5%
Q2 2026Aug 5, 2026 · After close+2.9%
Q1 2026May 6, 2026 · After close+1.2%
Q4 2025Mar 4, 2026−0.5%
Q3 2025Nov 5, 2025 · After close+12.9%
Q2 2025Aug 6, 2025 · After close+1.1%
Q1 2025May 6, 2025 · Before open−0.2%
Q4 2024Feb 26, 2025 · After close−2.0%
Q3 2024Nov 6, 2024 · After close+0.4%
Q2 2024Jul 31, 2024 · After close+2.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−1.7%
Q4 2023Feb 29, 2024 · After close−0.3%
Q3 2023Nov 1, 2023 · After close+6.9%
Q2 2023Aug 2, 2023 · After close0.0%
Q1 2023May 9, 2023 · After close+5.5%
Q4 2022Feb 28, 2023 · After close−5.8%
Q3 2022Nov 9, 2022 · After close+6.1%
Q2 2022Jul 27, 2022 · After close−3.0%
Q1 2022Apr 27, 2022 · After close+3.1%
Q4 2021Feb 9, 2022 · After close+13.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck30 slidesAugust 2026
Investor Presentation (May 2024)Investor deck28 slidesMay 13, 2024
Technical Presentation (November 2023)Technical7 slidesNov 6, 2023
Investor Presentation (May 2023)Investor deck22 slidesMay 24, 2023
Investor Presentation (September 2022)Investor deck21 slidesSep 14, 2022
Investor Presentation (April 2022)Investor deck22 slidesApr 7, 2022
Investor Presentation (December 2021)Investor deck17 slidesDec 13, 2021
Proxy Contest (April 2017)Proxy contest12 slidesApr 18, 2017
Proxy Contest (April 2017)Proxy contest20 slidesApr 12, 2017
Proxy Contest (April 2017)Proxy contest4 slidesApr 3, 2017
All 17 decks
DeckKindSlidesDate
Proxy Contest (April 2017)Proxy contest28 slidesApr 3, 2017
Proxy Contest (March 2017)Proxy contest66 slidesMar 30, 2017
Proxy Contest (March 2017)Proxy contest32 slidesMar 28, 2017
Proxy Contest (March 2017)Proxy contest19 slidesMar 27, 2017
Proxy Contest (March 2017)Proxy contest24 slidesMar 23, 2017
Proxy Contest (March 2017)Proxy contest28 slidesMar 7, 2017
Investor Presentation (March 2016)Investor deck18 slidesMar 8, 2016

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue411.3M358.7M310.5M331.3M391.9M336.8M261.0M261.0M217.2M133.6M
Cost of revenue117.6M36.6M42.6M13.8M13.8M1.79M01.35M1.39M
Gross profit307.7M296.2M246.0M317.5M391.9M336.8K261.0M261.0M217.2M132.2M
Research and development30.6M13.7M33.9M41.4M576.0K1.79M001.35M1.39M
Selling, general and administrative113.3M115.7M98.2M63.5M16.2M13.9M14.7M22.8M32.3M23.2M
Operating income163.7M166.9M113.9M207.0M375.1M321.1M246.4M238.3M183.6M109.0M
Depreciation and amortization40.2M39.9M35.7M19.5M13.8M13.8M13.9M13.9M14.0M14.0M
EBITDA204.0M206.7M149.6M226.5M388.9M335.0M260.2M252.1M197.6M122.9M
Interest expense16.7M22.2M19.2M15.8M19.1M18.3M18.7M24.0M43.6M52.4M
Income before tax326.9M37.4M194.1M286.9M445.3M354.2M232.9M210.3M134.3M59.6M
Income tax55.7M14.0M14.4M66.7M76.4M60.4M41.9M-196.1M4.00K95.0K
Net income271.2M23.4M179.7M213.9M265.9M224.4M157.3M395.1M134.1M59.5M
Earnings per share, basic4.020.372.753.073.242.211.553.921.250.54
Earnings per share, diluted3.300.362.202.372.872.021.433.531.170.53

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents550.9M305.0M193.5M291.0M201.5M246.5M278.1M62.4M73.3M118.0M
Short-term investments15.7M107.5M0403.0M0072.7M52.5M55.7M32.4M
Receivables35.0M86.4M84.1M64.1M110.7M93.9M79.4M83.3M70.5M46.8M
Inventory39.2M33.7M40.7M55.9M0-93.9M-79.4M-83.3M-754.0K-46.8M
Current assets727.5M554.3M344.2M443.5M313.7M342.1M431.2M199.0M200.4M198.0M
Property, plant and equipment1.55M514.0K483.0K170.0K12.0K28.0K33.0K160.0K209.0K368.0K
Goodwill17.9M17.9M17.9M26.7M000
Total assets1.64B1.30B1.24B1.23B926.4M999.6M724.8M548.2M367.3M379.0M
Accounts payable4.97M2.13M6.72M2.94M27.0K66.0K10.0K11.0K601.0K128.0K
Current liabilities49.7M236.1M38.1M135.0M5.81M6.11M5.37M5.70M34.7M20.0M
Long-term debt257.7M256.3M446.2M444.2M394.7M385.5M377.1M382.9M574.4M708.3M
Total debt257.7M448.3M446.2M540.4M394.7M385.5M377.1M382.9M574.4M716.1M
Total liabilities462.3M609.9M568.6M665.7M400.5M391.7M382.7M389.1M610.0M732.0M
Shareholders' equity1.17B691.2M675.0M565.8M414.7M539.9M313.5M153.6M-242.9M-353.0M
Shares outstanding74.6M62.7M63.3M69.2M69.6M101.4M101.3M101.1M101.3M101.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations196.9M188.7M141.1M201.7M363.8M313.1M257.5M223.5M141.7M61.0M
Capital spending-1.13M-270.0K-411.0K-67.0K0-13.0K-12.0K00-278.0K
Free cash flow195.8M188.4M140.7M201.7M363.8M313.1M257.4M223.5M141.7M60.7M
Cash from investing40.5M-63.8M-66.8M-56.6M43.7M-314.9M-18.0M3.52M-23.2M-4.58M
Cash from financing8.55M-13.5M-171.8M-55.6M-452.5M-29.8M-23.8M-238.0M-163.2M-97.6M
Dividends paid-96.3M00-11.0K-80.0K-281.0K-960.0K
Share buybacks-4.53M-14.8M-75.7M-8.50M-394.1M000-97.5M-78.1M
Change in cash246.0M111.5M-97.5M89.5M-45.0M-31.6M215.7M-10.9M-44.7M-41.2M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2026Insider tradeSEC
8-K · Current reportMay 18, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 4, 2026Offer documentSEC
8-K · Current reportMay 4, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
10-K/A · Annual report, amendedMar 27, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
DEF 14A · Proxy statementMar 24, 2026Meeting noticeSEC
8-K · Current reportFeb 25, 2026ResultsSEC
10-K · Annual reportFeb 25, 2026Annual reportSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 26, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 8, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 3, 2025Big-stake noticeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
4 · Change in ownershipAug 22, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
8-K · Current reportMay 21, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 28, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 8, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2025Meeting noticeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
10-K/A · Annual report, amendedMar 24, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 17, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedMar 17, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 12, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
10-K · Annual reportFeb 26, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025ResultsSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 27, 2025Big-stake noticeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
UPLOAD · Letter from the SECNov 1, 2024Other filingsSEC
CORRESP · Letter to the SECSep 26, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 13, 2024Other filingsSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
10-Q · Quarterly reportJul 31, 2024Quarterly reportSEC
8-K · Current reportJul 31, 2024ResultsSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Meeting outcomeSEC
4 · Change in ownershipMay 21, 2024Insider tradeSEC
4 · Change in ownershipMay 21, 2024Insider tradeSEC
SC 13G · Big-stake noticeMay 13, 2024Big-stake noticeSEC
8-K · Current reportMay 13, 2024Current reportSEC
ARS · Annual report to shareholdersMay 8, 2024Annual reportSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
SC 13D · Big-stake noticeMay 8, 2024Big-stake noticeSEC
3 · Initial statement of ownershipMay 1, 2024Insider tradeSEC
8-K · Current reportApr 29, 2024Management or board changeSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
10-K/A · Annual report, amendedMar 22, 2024Annual reportSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
10-K/A · Annual report, amendedMar 4, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedMar 4, 2024Big-stake noticeSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 22, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJan 10, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 17, 2023Insider tradeSEC
S-8 · Registration statement for employee plansNov 13, 2023Offer documentSEC
8-K · Current reportNov 6, 2023Current reportSEC
10-Q · Quarterly reportNov 1, 2023Quarterly reportSEC
8-K · Current reportNov 1, 2023ResultsSEC
4 · Change in ownershipAug 31, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 31, 2023Insider tradeSEC
4 · Change in ownershipAug 31, 2023Insider tradeSEC
8-K · Current reportAug 25, 2023Management or board changeSEC
8-K · Current reportAug 7, 2023Current reportSEC
4 · Change in ownershipAug 2, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 2, 2023Insider tradeSEC
10-Q · Quarterly reportAug 2, 2023Quarterly reportSEC
8-K · Current reportAug 2, 2023ResultsSEC
SC 13D/A · Big-stake notice, amendedJul 11, 2023Big-stake noticeSEC
8-K · Current reportJul 11, 2023Management or board changeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 7, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
4 · Change in ownershipMay 24, 2023Insider tradeSEC
8-K · Current reportMay 24, 2023Current reportSEC
8-K · Current reportMay 23, 2023Meeting outcomeSEC
4 · Change in ownershipMay 23, 2023Insider tradeSEC
4/A · Change in ownership, amendedMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
DEFA14A · Additional proxy materialMay 17, 2023Meeting noticeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 15, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMay 15, 2023Big-stake noticeSEC
8-K · Current reportMay 9, 2023ResultsSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 28, 2023Management or board changeSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
4 · Change in ownershipApr 17, 2023Insider tradeSEC
10-K/A · Annual report, amendedMar 20, 2023Annual reportSEC
4 · Change in ownershipMar 14, 2023Insider tradeSEC
8-K · Current reportFeb 28, 2023ResultsSEC
10-K · Annual reportFeb 28, 2023Annual reportSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 1, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeJan 20, 2023Big-stake noticeSEC
4 · Change in ownershipJan 12, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC
3 · Initial statement of ownershipJan 6, 2023Insider tradeSEC
8-K · Current reportJan 4, 2023Management or board changeSEC
4 · Change in ownershipNov 22, 2022Insider tradeSEC
10-Q · Quarterly reportNov 9, 2022Quarterly reportSEC
8-K · Current reportNov 9, 2022ResultsSEC
8-K/A · Current report, amendedOct 28, 2022Acquisition or disposalSEC
8-K · Current reportSep 14, 2022Current reportSEC
3 · Initial statement of ownershipAug 26, 2022Insider tradeSEC
8-K · Current reportAug 23, 2022Current reportSEC
4 · Change in ownershipAug 22, 2022Insider tradeSEC
8-K · Current reportAug 22, 2022Acquisition or disposalSEC
SC TO-T/AAug 22, 2022Acquisition or disposalSEC
SC TO-T/AAug 16, 2022Acquisition or disposalSEC
10-Q · Quarterly reportJul 27, 2022Quarterly reportSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Innoviva, Inc.’s releases

Common shares
72,245,485
Fully diluted
72,245,485

Fully diluted

LineShares
Common shares72,245,485

Share count over time

CountShares
Nov 22, 202672,245,485

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
BlackRock12.6MUS$266M+1.01MNov 13, 2026
Vanguard7.97MUS$169M−32,834Nov 16, 2026
Dimensional4.51MUS$95.7M+18,999Nov 4, 2026
Renaissance Technologies3.65MUS$77.4M−386KNov 12, 2026
State Street3.5MUS$74.2M+232KNov 12, 2026
Millennium2.56MUS$54.3M+20,512Nov 16, 2026
Systematic Financial Management LP2.06MUS$43.8M+40,613Nov 16, 2026
Geode Capital2.06MUS$43.7M−16,557Nov 6, 2026
Sarissa Capital Management LP1.89MUS$40.1MNo changeNov 16, 2026
Morgan Stanley1.72MUS$36.5M+501KNov 13, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Goldman Sachs1.62MUS$34.4M+2,655Nov 16, 2026
Bank of America1.48MUS$31.3M−192KNov 16, 2026
Qube Research & Technologies Ltd1.22MUS$25.8M+244KNov 13, 2026
UBS1.21MUS$25.7M+525KNov 16, 2026
Invesco1.18MUS$25.1M+451KNov 12, 2026
Schwab1.15MUS$24.4M+433Nov 16, 2026
Royce & Associates LP1.12MUS$23.7M−54,433Nov 9, 2026
DWS1.09MUS$23.1M+170KNov 6, 2026
Two Sigma1.05MUS$22.3M+20,446Nov 16, 2026
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main925KUS$19.6M+94,890Nov 16, 2026
William Blair Investment Management, LLC833KUS$17.7M+191KNov 6, 2026
Northern Trust815KUS$17.3M−16,626Nov 16, 2026
American Century756KUS$16M−742KNov 20, 2026
Nuveen735KUS$15.6M+67,751Nov 10, 2026
Marshall Wace, LLP630KUS$13.4M−824KNov 13, 2026
Victory Capital606KUS$12.9M−19,486Nov 10, 2026
Bridgeway Capital Management, LLC544KUS$11.5M+194KNov 16, 2026
AQR Capital Management LLC535KUS$11.3M−14,840Nov 16, 2026
BNY504KUS$10.7M−7,364Nov 5, 2026
Principal487KUS$10.3M+70,381Nov 2, 2026
Allianz435KUS$9.22M−51,093Nov 16, 2026
D. E. Shaw & Co., Inc.433KUS$9.18M+267KNov 16, 2026
Empowered Funds, LLC418KUS$8.86M+91,501Nov 13, 2026
Hrt Financial LP405KUS$8.59M+161KNov 13, 2026
Balyasny Asset Management L.P.368KUS$7.81M+82,731Nov 16, 2026
Assetmark, Inc367KUS$7.78M+139KOct 21, 2026
First Trust340KUS$7.21M+53,968Nov 12, 2026
Franklin Templeton306KUS$6.5M+32,374Nov 12, 2026
Uniplan Investment Counsel, Inc.299KUS$6.33M+34,396Nov 12, 2026
Baird Financial Group, Inc.273KUS$5.79M−1,264Nov 13, 2026
Ameriprise272KUS$5.76M+61,183Nov 16, 2026
Envestnet Asset Management Inc250KUS$5.29M+31,926Nov 16, 2026
Public Sector Pension Investment Board246KUS$5.15M+4,828Nov 10, 2026
Assenagon Asset Management S.A.232KUS$4.91M−657KOct 15, 2026
Russell Investments Group, Ltd.230KUS$4.87M−249KNov 6, 2026
Trexquant Investment LP221KUS$4.7MNewNov 16, 2026
Los Angeles Capital Management LLC219KUS$4.64M+218KNov 12, 2026
Martingale Asset Management L P203KUS$4.3M+37,436Nov 12, 2026
Exchange Traded Concepts, LLC195KUS$4.13M+30,167Oct 28, 2026
Creative Planning191KUS$4.06M−3,467Nov 2, 2026

This page holds 50 of 284 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
iShares Core S&P Small-Cap ETF4.23MUS$96M−37,031Jun 30, 2026
Vanguard Total Stock Market Index Fund2.23MUS$50.7MNo changeJun 30, 2026
iShares Russell 2000 ETF1.94MUS$44.1M+128KJun 30, 2026
Vanguard Small-Cap Index Fund1.61MUS$36.5M−15,226Jun 30, 2026
Avantis U.S. Small Cap Value ETF1.44MUS$30.8M−228KMay 31, 2026
Vanguard Small-Cap Value Index Fund1.02MUS$23.1M−14,377Jun 30, 2026
U.S. Small Cap Value Portfolio1.01MUS$21.1M+33,477Jul 31, 2026
Fidelity Small Cap Index Fund826KUS$17.3M+85,147Jul 31, 2026
Vanguard Extended Market Index Fund803KUS$18.2M+13,014Jun 30, 2026
iShares Russell 2000 Value ETF707KUS$16.1M+631KJun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Column Small Cap Select Fund660KUS$14.1M+55,862May 31, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF644KUS$14.6M+3,310Jun 30, 2026
U.S. Targeted Value Portfolio551KUS$11.6MNo changeJul 31, 2026
Invesco Pharmaceuticals ETF544KUS$11.4M+127KJul 31, 2026
Dimensional U.S. Targeted Value ETF508KUS$10.7M−3,144Jul 31, 2026
Dimensional US Small Cap Value ETF426KUS$8.93M+17,427Jul 31, 2026
Vanguard Tax-Managed Small-Cap Fund403KUS$9.15MNo changeJun 30, 2026
Vanguard Russell 2000 Index Fund385KUS$8.26M+73,587May 31, 2026
iShares S&P Small-Cap 600 Growth ETF373KUS$8.48M+12,321Jun 30, 2026
Fidelity Extended Market Index Fund367KUS$7.87M−6,751May 31, 2026
Schwab U.S. Small-Cap ETF342KUS$7.32M−1,711May 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF331KUS$7.53M+82,299Jun 30, 2026
U.S. Small Cap Portfolio324KUS$6.79MNo changeJul 31, 2026
PIMCO RAE US Small Fund312KUS$7.08M−50,315Jun 30, 2026
Royce Small-Cap Opportunity Fund311KUS$7.07M+11,703Jun 30, 2026
William Blair Small Cap Value Fund300KUS$6.82M+85,097Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF284KUS$6.46M+20,941Jun 30, 2026
Pacer US Small Cap Cash Cows 100 ETF281KUS$5.89M−66,393Jul 31, 2026
U.S. Micro Cap Portfolio274KUS$5.75M+2,487Jul 31, 2026
WPG Partners Select Small Cap Value Fund262KUS$5.61M+23,043May 31, 2026
Applied Finance Explorer Fund253KUS$5.31M+3,022Jul 31, 2026
Vanguard S&P Small-Cap 600 Index Fund246KUS$5.27M+2,080May 31, 2026
iShares S&P Small-Cap 600 Value ETF246KUS$5.58M−38,105Jun 30, 2026
Dimensional U.S. Small Cap ETF242KUS$5.07M−57Jul 31, 2026
Nuveen Quant Small/Mid Cap Equity Fund240KUS$5.03MNo changeJul 31, 2026
Schwab Fundamental U.S. Small Company ETF239KUS$5.12M−23,543May 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF235KUS$5.33M+13,806Jun 30, 2026
Royce Small-Cap Fund229KUS$5.19M+17,583Jun 30, 2026
Vanguard Health Care Index Fund213KUS$4.56M+32,273May 31, 2026
Goldman Sachs Small Cap Value Insights Fund200KUS$4.19MNewJul 31, 2026
Dimensional U.S. Core Equity 2 ETF199KUS$4.17MNo changeJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account195KUS$4.42MNo changeJun 30, 2026
First Trust Small Cap Core AlphaDEX Fund192KUS$4.03M+43,080Jul 31, 2026
EA Bridgeway Omni Small-Cap Value ETF186KUS$3.98MNewJun 30, 2026
Schwab Small-Cap Index Fund184KUS$3.86M+19,572Jul 31, 2026
iShares U.S. Pharmaceuticals ETF182KUS$4.14M−16,225Jun 30, 2026
Omni Small-Cap Value Fund175KUS$3.97MNewJun 30, 2026
VictoryShares Small Cap Free Cash Flow ETF163KUS$3.71M−6,994Jun 30, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Value ETF146KUS$3.32M−9,565Jun 30, 2026
Master Small Cap Index Series141KUS$3.21M+39,350Jun 30, 2026

This page holds 50 of 316 holders. Open Shareholders

Big stakes

HolderStakeSharesDate
BlackRock, Inc.15.40%11.1MSep 30, 2026
Dimensional Fund Advisors LP5.80%4.36MDec 31, 2025
Vanguard Portfolio Management LLC5.79%4.29MMar 31, 2026
Renaissance Technologies LLC5.63%4.21MDec 31, 2025
Vanguard Capital Management LLC5.01%3.7MJun 30, 2026
Sarissa Capital Management LP4.70%2.97MMar 13, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Julian Baker
Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past)
Director · Apr 26, 2006 – Apr 26, 2006 · Past
Barbara Duncan
Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Feb 3, 2023); Atea Pharmaceuticals, Inc. (Director · Since at least Oct 29, 2020); Ovid Therapeutics Inc. (Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee · Since at least Jun 14, 2017); Fusion Pharmaceuticals Inc (Director · Oct 30, 2020 – Jun 4, 2024 · Past); Immunomedics Inc (Director · Mar 5, 2019 – Oct 23, 2020 · Past); Jounce Therapeutics Inc (Director · Jan 26, 2017 – May 3, 2023 · Past); Adaptimmune Therapeutics PLC (Director · Jun 23, 2016 – Jul 1, 2022 · Past); Aevi Genomic Medicine LLC (Director · Jul 22, 2015 – Feb 3, 2020 · Past); Intercept Pharmaceuticals Inc (Chief Accounting Officer · Oct 10, 2012 – Oct 3, 2016 · Past)
Director · Nov 18, 2016 – Apr 20, 2017 · Past
William Young
Other companies: Autolus Therapeutics plc (Chair of the Nominating and Governance Committee, Member of the Research & Development Committee · Since at least Mar 18, 2026); Praxis Precision Medicines, Inc. (Director · Since at least Oct 15, 2020); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 26, 2022 · Past); Vertex Pharmaceuticals Incorporated (Director · May 7, 2014 – Jun 1, 2020 · Past); NanoString Technologies Inc (Director · Jun 25, 2013 – May 6, 2024 · Past); BioMarin Pharmaceutical Inc. (Director · Sep 22, 2010 – Jun 10, 2015 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Apr 27, 2006 · Past); Biogen Inc. (Director · Jan 9, 2006 – Jan 8, 2014 · Past)
Director · Apr 26, 2006 – May 22, 2014 · Past
Sapna Srivastava
Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Aura Biosciences, Inc. (Director · Since at least Oct 28, 2021); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Tourmaline Bio Inc. (Director · Since at least May 6, 2021); Social Capital Suvretta Holdings Corp II (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Intellia Therapeutics, Inc. (Chief Financial & Stategy Offr · May 5, 2016 – May 5, 2016 · Past); Medavail Holdings Inc (Director · Feb 8, 2013 – Jan 12, 2015 · Past)
Director · Jan 1, 2023 – Jun 17, 2024 · Past
George Bickerstaff
Other companies: CareDx, Inc. (Director · Since at least Jul 16, 2014); Sio Gene Therapies Inc (Director · Feb 11, 2018 – Apr 15, 2019 · Past); Inovio Pharmaceuticals, Inc. (Director · Mar 21, 2017 – Mar 21, 2018 · Past); Ariad Pharmaceuticals Inc (Director · May 4, 2016 – Feb 16, 2017 · Past); BMP Sunstone CORP (Director · Apr 28, 2008 – Apr 28, 2008 · Past); Vion Pharmaceuticals Inc (Director · Jun 28, 2006 – Dec 11, 2008 · Past)
Director · Dec 19, 2017 – Apr 25, 2022 · Past
James L. Tyree
Other companies: Genelux Corporation (Lead Independent Director · Since at least Jan 25, 2023); Assertio Holdings, Inc. (Director · May 19, 2020 – Mar 14, 2024 · Past); Depomed Inc (Director · Oct 17, 2016 – May 8, 2018 · Past); ChemoCentryx Inc. (Director · Jun 5, 2012 – Oct 20, 2022 · Past); Abbott Laboratories (Executive Vice President · Feb 14, 2006 – Feb 27, 2009 · Past)
Director · Jun 2, 2014 – Apr 20, 2017 · Past
Josephine Linden
Other companies: Lands' End Inc (Director · Since at least Mar 20, 2014); Trine II Acquisition Corp (Director · Nov 2, 2021 – Nov 2, 2021 · Past); Desktop Metal Inc (Director · Mar 14, 2019 – Mar 14, 2019 · Past); Sears Hometown and Outlet Stores Inc (Director · Oct 11, 2012 – Oct 23, 2019 · Past); Bally Technologies Inc (Director · Apr 1, 2011 – Nov 21, 2014 · Past)
Board Member · Since at least May 18, 2026
Kostas D Odysseas
Other companies: Amarin Corporation plc (Director · Since at least Feb 28, 2023); Armata Pharmaceuticals, Inc. (Director · Since at least Feb 12, 2020); Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past); Viskase Holdings, Inc. (Director · Sep 25, 2013 – Sep 25, 2013 · Past); Savara, Inc. (Director · Feb 2, 2010 – Jun 30, 2010 · Past)
Director · Dec 19, 2017 – Jun 17, 2024 · Past
Mathai Mammen
Other companies: Parabilis Medicines, Inc. (Chairman, CEO and President · Since at least Jun 9, 2026); Johnson & Johnson (EVP, Pharm, R&D · Jan 3, 2022 – Feb 14, 2022 · Past); 10x Genomics, Inc. (Director · Sep 11, 2019 – Jun 11, 2024 · Past); Theravance Biopharma, Inc. (SVP, Research & Development · Oct 1, 2014 – Mar 15, 2016 · Past)
SVP, Research & Early Clin Dev · Jan 4, 2008 – Aug 20, 2014 · Past
Terrence C Kearney
Other companies: AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Acceleron Pharma Inc (Director · Jul 14, 2014 – Nov 19, 2021 · Past); Vertex Pharmaceuticals Incorporated (Director · May 17, 2011 – May 1, 2024 · Past); Hospira Inc (Chief Operating Officer · May 17, 2006 – Dec 15, 2010 · Past)
Director · Oct 30, 2014 – Apr 24, 2015 · Past
All 48 people
PersonSeat
Eve Elizabeth Slater
Other companies: Aceragen Inc. (Director · Jun 16, 2010 – Jun 8, 2015 · Past); Phase Forward Inc (Director · Feb 26, 2007 – Feb 26, 2007 · Past); Vertex Pharmaceuticals Incorporated (Director · Mar 23, 2006 – Jun 1, 2007 · Past)
Director · Apr 26, 2006 – Apr 25, 2007 · Past
George Whitesides
Other companies: Lyra Therapeutics, Inc. (Woodford L. and Ann A. Flowers University Professor, Harvard University · Since at least Apr 30, 2020); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 27, 2021 · Past); Rohm & Haas Co (Director · Jan 9, 2006 – Apr 1, 2009 · Past)
Director · Apr 26, 2006 – May 22, 2014 · Past
Henrietta Fore
Other companies: General Mills, Inc. (Director · Jun 24, 2014 – Sep 26, 2017 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Aug 11, 2017 · Past); Exxon Mobil Corporation (Director · Feb 29, 2012 – Dec 31, 2017 · Past)
Director · Oct 20, 2010 – May 22, 2014 · Past
Leonard M Blum
Other companies: EyePoint, Inc. (See Remarks · May 14, 2018 – May 14, 2018 · Past); Theravance Biopharma, Inc. (Sr VP, Chief Comm. Officer · Oct 1, 2014 – Feb 20, 2016 · Past); Icos Corp (Senior VP, Sales and Marketing · Dec 29, 2005 – Jan 29, 2007 · Past)
Sr VP, Chief Comm. Officer · Jul 30, 2007 – Aug 20, 2014 · Past
Mark DiPaolo
Other companies: OneIM Acquisition Corp. (Director · Since at least Jan 13, 2026); Amarin Corporation plc (Director · Feb 28, 2023 – Apr 18, 2025 · Past); Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past)
Director · Since at least Apr 24, 2019
Rick E Winningham
Other companies: Theravance Biopharma, Inc. (CHIEF EXECUTIVE OFFICER, Director · Since at least May 14, 2014); Jazz Pharmaceuticals plc (Director · Since at least May 4, 2010); OncoMed Pharmaceuticals Inc (Director · Jun 24, 2015 – Jun 22, 2018 · Past)
Director · Feb 8, 2006 – Aug 15, 2014 · Past
Robert V Gunderson Jr
Other companies: Andersen Group Inc. (Director · Since at least Dec 16, 2025); Vitae Pharmaceuticals Inc (Director · Sep 24, 2014 – Oct 24, 2016 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 27, 2021 · Past)
Director · Apr 26, 2006 – May 22, 2014 · Past
Sarah J. Schlesinger
Other companies: Armata Pharmaceuticals, Inc. (Director · Since at least Feb 12, 2020); The Medicines Company (Director · Feb 22, 2018 – Jan 6, 2020 · Past); Ariad Pharmaceuticals Inc (Director · Jul 15, 2013 – Feb 13, 2017 · Past)
Board Member · Since at least Feb 12, 2018
Frank Pasqualone
Other companies: Enveric Biosciences, Inc. (Director · Since at least Jul 13, 2022); Theravance Biopharma, Inc. (SVP, CHIEF BUSINESS OFFICER · May 14, 2014 – Nov 19, 2021 · Past)
Sr. Vice President, Operations · Jan 13, 2014 – Jan 23, 2014 · Past
Jeffrey David Jonker
Other companies: Metacrine Inc (Director · Mar 17, 2021 – May 18, 2022 · Past); Theravance Biopharma, Inc. (Senior VP, Corp. & Bus. Dev. · May 14, 2014 – Jun 3, 2014 · Past)
Senior VP, Corp. & Bus. Dev. · Oct 14, 2013 – Oct 22, 2013 · Past
Michael Faerm
Other companies: AtaiBeckley Inc. (Chief Financial Officer · Since at least Feb 19, 2026); Viracta Therapeutics Inc (Chief Financial Officer · May 13, 2024 – May 14, 2024 · Past)
Sr VP & Chief Business Officer · Jul 14, 2015 – Nov 20, 2017 · Past
Peter S Ringrose
Other companies: Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 30, 2019 · Past); Rigel Pharmaceuticals, Inc. (Director · May 28, 2010 – May 17, 2018 · Past)
Director · Apr 27, 2010 – May 22, 2014 · Past
Bradford J Shafer
Other companies: Theravance Biopharma, Inc. (EVP, Gen. Counsel, Secretary · Sep 1, 2014 – Aug 20, 2021 · Past)
Sr VP, Gen. Counsel, Secretary · Feb 8, 2006 – Aug 20, 2014 · Past
Burton G Malkiel
Other companies: Theravance Biopharma, Inc. (Director · May 14, 2014 – May 2, 2023 · Past)
Director · Jul 3, 2007 – May 22, 2014 · Past
David Altarac
Other companies: Entasis Therapeutics Holdings Inc (Chief Medical Officer · Nov 4, 2019 – Jul 7, 2022 · Past)
Chief Medical Officer, IST · Since at least Oct 19, 2026
Deborah Birx
Other companies: Armata Pharmaceuticals, Inc. (Chief Executive Officer · Since at least Jul 10, 2023)
Director · Mar 9, 2021 – May 22, 2023 · Past
Derek A Small
Other companies: Assembly Biosciences, Inc. (Director · Jul 11, 2014 – Jan 2, 2020 · Past)
Director · Since at least Apr 29, 2024
Jules Haimovitz
Other companies: Armata Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2021)
Director · Since at least Feb 12, 2018
Junning Lee
Other companies: Theravance Biopharma, Inc. (Sr. VP, Technical Operations · Sep 1, 2014 – Feb 20, 2017 · Past)
Sr. VP, Technical Operations · Jan 6, 2014 – Aug 20, 2014 · Past
Larry G Edwards
Other companies: La Jolla Pharmaceutical Co (Chief Executive Officer, Director · Dec 10, 2020 – Aug 22, 2022 · Past)
CEO of La Jolla Pharmaceutical · Aug 22, 2022 – Aug 22, 2022 · Past
Margaret Koziel
Other companies: Axcella Health Inc (Chief Medical Officer · Dec 1, 2021 – Mar 1, 2023 · Past)
Chief Medical Officer · Jul 31, 2023 – Jul 31, 2023 · Past
Matthew Ronsheim
Other companies: Entasis Therapeutics Holdings Inc (Chief of Pharma Sciences & MFG · Sep 9, 2020 – Jul 7, 2022 · Past)
See Remarks · Jan 1, 2024 – May 20, 2024 · Past
Michael Kitt
Other companies: Portola Pharmaceuticals Inc (Senior VP and CMO · May 21, 2013 – May 21, 2013 · Past)
Sr. Vice President Development · Feb 8, 2006 – Jun 2, 2008 · Past
P Roy Vagelos
Other companies: Regeneron Pharmaceuticals, Inc. (Director · Dec 31, 2005 – Apr 3, 2023 · Past)
Director · Apr 26, 2006 – Dec 23, 2009 · Past
Stephen Basso
Other companies: Inozyme Pharma Inc (SVP Finance (PFO) · Jul 23, 2020 – Mar 24, 2021 · Past)
Chief Financial Officer · Since at least Aug 21, 2023
Arthur L CampbellSr. VP, Technical Operations · Feb 8, 2006 – Jan 29, 2008 · Past
David PattiCorporate Communications · Since at least Dec 15, 2025
Eleanor BarisserInvestor Relations Internal · Since at least May 6, 2026
Eric dEsparbesSVP and CFO · Oct 9, 2014 – May 20, 2018 · Past
Geoffrey HulmeInterim Principal Exec Officer · May 21, 2018 – May 20, 2020 · Past
Irwin TendlerHead of Investor Relations · Since at least Aug 12, 2026
Marianne ZhenChief Accounting Officer · Since at least Aug 3, 2018
Patrick PA HumphreyExecutive VP Research · Feb 8, 2006 – Dec 10, 2007 · Past
Paul PepeDirector · Jun 2, 2014 – Apr 20, 2017 · Past
Pavel RaifeldChief Executive Officer · Since at least May 20, 2020
Ronn LoewenthalDirector · Apr 26, 2006 – May 2, 2006 · Past
Theodore J Witek JrSr. VP & Chief Scientific Off. · Jul 1, 2014 – Aug 20, 2018 · Past
William H WaltripDirector · Apr 26, 2016 – Apr 20, 2017 · Past

Open People

Log in to ask 6ix AI your own questions about Innoviva, Inc.